Figure 1.
JNK1 is overexpressed and hyperphosphorylated in primary human CLL. (A and B) Gene sets, GDS3902 (n = 16) and GDS4168 (n = 36) published in the GEO database comparing B cells from healthy donors with CLLs were analyzed regarding JNK1 mRNA expression (unpaired t test, *P < 0.05; **P < 0.01). (C) TaqMan PCR was performed for JNK1 and GAPDH from RNA extracted from CLL patient samples (n = 20, patients #1–20) and CD19+ lymphocytes from healthy donors (n = 7). JNK1 transcript levels were normalized to GAPDH and healthy donor control was set to 1 (patient characteristics in Table S1; unpaired t test, *P < 0.05). (D) Protein expression of p-JNK1 and total JNK1 in CLL patient samples (n = 12), and CD19+ lymphocytes from healthy donors (n = 2). β-Actin was used as a loading control and MEC1 cells as a positive control. Patients with unmutated IGHV are marked with green arrows. (E and F) Relative expression of p-JNK1 and total JNK1 were compared with β-actin in CLL patient samples (n = 21) and CD19+ lymphocytes from healthy donors (n = 7 controls). Western blots: Fig. 1 D and data not shown (unpaired t test, ***P < 0.001, ****P < 0.0001). (G) Relative phospho-JNK1 compared with total JNK1 in IGHV mutated (n = 13) and unmutated (n = 8) CLL patient samples (unpaired t test, ****P < 0.0001). (H) JNK1 level (H-score) in reactive lymph nodes (n = 21) and lymph nodes from CLL patients (n = 28) (unpaired t test, **P < 0.01). (I) Phospho-JNK1 levels in the same samples (unpaired t test, **P < 0.01). (J) Representative examples of IHC images from lymph nodes of CLL patients (upper row) or reactive lymph nodes (lower row) stained for total JNK1 (first and last column) or phospho-JNK1 (medium column). Source data are available for this figure: SourceData F1.

JNK1 is overexpressed and hyperphosphorylated in primary human CLL. (A and B) Gene sets, GDS3902 (n = 16) and GDS4168 (n = 36) published in the GEO database comparing B cells from healthy donors with CLLs were analyzed regarding JNK1 mRNA expression (unpaired t test, *P < 0.05; **P < 0.01). (C) TaqMan PCR was performed for JNK1 and GAPDH from RNA extracted from CLL patient samples (n = 20, patients #1–20) and CD19+ lymphocytes from healthy donors (n = 7). JNK1 transcript levels were normalized to GAPDH and healthy donor control was set to 1 (patient characteristics in Table S1; unpaired t test, *P < 0.05). (D) Protein expression of p-JNK1 and total JNK1 in CLL patient samples (n = 12), and CD19+ lymphocytes from healthy donors (n = 2). β-Actin was used as a loading control and MEC1 cells as a positive control. Patients with unmutated IGHV are marked with green arrows. (E and F) Relative expression of p-JNK1 and total JNK1 were compared with β-actin in CLL patient samples (n = 21) and CD19+ lymphocytes from healthy donors (n = 7 controls). Western blots: Fig. 1 D and data not shown (unpaired t test, ***P < 0.001, ****P < 0.0001). (G) Relative phospho-JNK1 compared with total JNK1 in IGHV mutated (n = 13) and unmutated (n = 8) CLL patient samples (unpaired t test, ****P < 0.0001). (H) JNK1 level (H-score) in reactive lymph nodes (n = 21) and lymph nodes from CLL patients (n = 28) (unpaired t test, **P < 0.01). (I) Phospho-JNK1 levels in the same samples (unpaired t test, **P < 0.01). (J) Representative examples of IHC images from lymph nodes of CLL patients (upper row) or reactive lymph nodes (lower row) stained for total JNK1 (first and last column) or phospho-JNK1 (medium column). Source data are available for this figure: SourceData F1.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal